"How is it that the person in charge has no clue about
"How is it that the person in charge has no clue about Leronlimab?"
He definitely has a clue, but he is thinking about a whole lot more things (like epidemiology and vaccines) and is a whole lot more interested in what the proven BPs like Gilead, Moderna, Roche, etc. have to say than a pipsqueak startup who's working on a strange new theory. He may not know very much at all about leronlimab.
On the other hand, he most likely knows WAY more valuable information than 'most any of us. A few well-placed sentences would be worth a heck of a lot more than all the articles and papers we can read and all the webinars and conference calls we can listen to.
"he is aware and is willfully not saying anything, not even a hint. Why?"
I think he did give a hint today. He mentioned mab for HIV looking promising. There are lots of mab's being discussed, but any HIV mab's besides leronlimab?
"only two answers are possible. One--because he doesn't want to mention any names before a drug has proved itself in the trial."
Certainly. It would be bordering on unprofessional for him to name leronlimab prematurely (like DJT naming HQC---mistake).
"Two--Fauci is a lead agent of the biotech-medical research complex--similar to the military-industrial complex..." surely that's true and will defend their interests. But he's not avoiding the L word to appease them. He's avoiding it because he's the embodiment of the system. He can scarcely conceive of lending an ear to the likes of Cytodyn before it has proved itself worthy. When it has, he will welcome us to the crowd.
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...
Continue Reading
What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...
Continue Reading
An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...
Continue Reading
Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...
Continue Reading
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...
Continue Reading
>
Top 5 Most Recently Viewed Articles
Understanding KeyBanc's Downgrade of Howmet Aerospace Howmet Aerospace Inc. (NYSE:HWM) recently saw a shift in its stock evaluation when KeyBanc moved its rating from Overweight to Sector Weight. This decision comes in response to a noticeable cooling in demand within the commercial aerospace industry, prompting analysts to reconsider their outlook on the company. Despite...
Continue Reading
Franklin Templeton Introduces New ETF Offerings Franklin Templeton recently announced the launch of two exciting new ETFs aimed at returning enhanced dividend income. These innovative investment products are the Franklin U.S. Dividend Multiplier ETF (XUDV) and the Franklin International Dividend Multiplier ETF (XIDV). Developed in collaboration with New Frontier and...
Continue Reading
Signs of Recovery in the Commercial Vehicle Market The commercial vehicle market is experiencing a notable recovery. According to the latest analysis from Work Truck Solutions, new commercial vehicle sales are revitalizing the industry, leading to advantageous effects in the used vehicle sector. As inventory levels stabilize, the ecosystem is transitioning into a phase...
Continue Reading
BELFOR Franchise Group Expands COOL-BINZ Franchise Locations BELFOR Franchise Group, known for its excellent residential and commercial services, has made significant advancements with the COOL-BINZ franchise. The company celebrates the onboarding of new franchise owners, successfully extending its reach into four different markets. Welcoming New Franchise Owners The...
Continue Reading
A Look into the Bread Crumbs Market and Its Future Growth The global bread crumbs market is poised for remarkable growth, with projections indicating an increase from USD 1.13 billion to USD 2.16 billion over the coming years. This growth represents a compound annual growth rate (CAGR) of 6.7%. The driving forces behind this robust expansion are evolving consumer...
Continue Reading